Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

3-1-2022

Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with
a Reduced Risk of Heart Failure Hospitalization in Patients with
Heart Failure with Preserved Ejection Fraction and Type 2
Diabetes Mellitus: A Real-World Study on a Diverse Urban
Population
Weijia Li
Albert Einstein College of Medicine of Yeshiva University

Adarsh Katamreddy
Albert Einstein College of Medicine of Yeshiva University

Rachna Kataria
Albert Einstein College of Medicine of Yeshiva University

Merle L. Myerson
Geisel School of Medicine at Dartmouth

Cynthia C. Taub
Albert Einstein College of Medicine of Yeshiva University
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa

Dartmouth Digital Commons Citation
Li, Weijia; Katamreddy, Adarsh; Kataria, Rachna; Myerson, Merle L.; and Taub, Cynthia C., "Sodium-Glucose
Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in
Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World
Study on a Diverse Urban Population" (2022). Dartmouth Scholarship. 4274.
https://digitalcommons.dartmouth.edu/facoa/4274

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Drugs - Real World Outcomes (2022) 9:53–62
https://doi.org/10.1007/s40801-021-00277-0

ORIGINAL RESEARCH ARTICLE

Sodium‑Glucose Cotransporter‑2 Inhibitor Use is Associated
with a Reduced Risk of Heart Failure Hospitalization in Patients
with Heart Failure with Preserved Ejection Fraction and Type 2
Diabetes Mellitus: A Real‑World Study on a Diverse Urban Population
Weijia Li1 · Adarsh Katamreddy1 · Rachna Kataria2 · Merle L. Myerson3 · Cynthia C. Taub2,3
Accepted: 10 August 2021 / Published online: 3 September 2021
© The Author(s) 2021

Abstract
Background Limited evidence-based therapies exist for the management of heart failure with preserved ejection fraction
(HFpEF). Sodium-glucose cotransporter-2 inhibitor (SGLT2i) use in patients with systolic heart failure (HFrEF) and type2-diabetes mellitus (T2DM) is associated with improved cardiovascular (CV) and renal outcomes.
Objective We sought to examine whether there is an association of SGLT2i use with improved CV outcomes in patients
with HFpEF.
Patients and methods We conducted a single-center, retrospective review of patients with HFpEF and T2DM. The cohort
was divided into two groups based on prescription of a SGLT2i or sitagliptin. The primary outcome was heart failure hospitalization (HFH); secondary outcomes were all-cause hospitalization and acute kidney injury (AKI).
Results After propensity score matching, there were 250 patients (89 in the SGLT2i group, 161 in the sitagliptin group),
with a mean follow-up of 295 days. Univariate Cox regression analysis showed that the SGLT2i group had a reduced risk of
HFH versus the sitagliptin group (hazard ratio (HR) 0.13; 95% confidence interval (CI) (0.05–0.36); p < 0.001). The SGLT2i
group had a decreased risk of all-cause hospitalization (HR 0.48; 95% CI (0.33–0.70); p < 0.001) and SGLT2i had a lower
risk of AKI (HR 0.39; 95% CI (0.20–0.74); p = 0.004).
Conclusions The use of SGLT2is is associated with a reduced incidence of HFH and AKI in patients with HFpEF and T2DM.

1 Introduction

Key Points

Heart failure (HF) with preserved ejection fraction
(HFpEF), also known as diastolic heart failure, is characterized by abnormalities of ventricular relaxation and compliance, resulting in decreased cardiac output and compromised organ perfusion [1]. More than 8 million Americans
live with all forms of HF and the total medical expenditure
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for HF is projected to reach US$53.1 billion in 2030, with
80% of the costs attributed to hospitalization [2]. Up to a
half of the patients with HF have HFpEF, which is defined
as left ventricular ejection fraction of ≥ 50% with defined
echocardiographic features and/or clinical evidence of
congestion [3]. However, while evidence-based therapies are available for heart failure with reduced ejection
(HFrEF), similar therapies for HFpEF are unknown [4, 5].
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a
novel class of cardiometabolic drugs, which have not only
shown conclusive benefits in patients with HFrEF [6–8],
but have also shown some promise in the management of
HFpEF [9]. The US Food and Drug Administration (FDA)
currently approves SGLT2is for type 2 diabetes mellitus
(T2DM) patients as an add-on therapy to metformin [10].
The blood pressure-lowering, weight-reducing, and antiinflammatory effects of SGLT2is are postulated to benefit
HFpEF patients independent of a glucose-lowering effect
[11]. Subgroup analysis of the recently published Effect
of Sotagliflozin on Cardiovascular Events in Patients With
Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) trial showed a consistent benefit of SGLT2is in the
total number of deaths from cardiovascular causes, hospitalizations, and urgent visits for heart failure patients
with left ventricular ejection fraction (LVEF) less than
and greater than 50%. However, only 21% of the cohort
had LVEF greater than 50%, and the trial was terminated
earlier than planned due to funding issues [12]. While
the results of this trial provided the first evidence for
the potential clinical benefit of SGLT2is in patients with
HFpEF, there remains a lack of definitive evidence on the
clinical benefits of SGLT2is in patients with HFpEF [13].
Another co-morbidity common in patients hospitalized
for heart failure is acute kidney injury (AKI), and is associated with worse clinical outcomes [14]. SGLT2is are
associated with improved renal outcomes, including progression to end-stage kidney disease, doubling of serum
creatinine, and renal death in patients with established
diabetes mellitus and chronic kidney disease (CKD) [15].
However, AKI has not been assessed as a clinical outcome
for the effects of SGLT2is in patients with HFpEF and
T2DM.
Therefore, we sought to assess the clinical impact of
SGLT2i use in patients with HFpEF and T2DM on hospitalizations for heart failure, all-cause hospitalizations, and
AKI incidence. While medication regimens for patients
with HFpEF and T2DM vary, we chose patients who were
prescribed sitagliptin (and not an SGLT2i) as a comparator
group while noting other relevant medications that were
background therapy for participants.
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2 Material and Methods
2.1 Study Design and Patient Population
This retrospective observational cohort study was conducted at Montefiore Medical Center, an inner-city tertiary
academic center with three main campuses. We included
patients older than 18 years of age, with a diagnosis of
HFpEF (ICD-10-CM I50.3 diastolic heart failure, I50.30
unspecified diastolic heart failure, I50.31, acute diastolic
heart failure, I50.32 chronic diastolic heart failure, I50.33
acute on chronic diastolic heart failure) with left ventricular
ejection fraction more than 50% and T2DM. All patients
were divided into two groups: the SGLT2i group and the
control group. The SGLT2i group included eligible patients
who were prescribed one of the FDA-approved SGLT2is
(canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin) between 1 January 2016 and 1 January 2020. The
control group included patients who were prescribed sitagliptin without any SGLT2i prescriptions during the same
period. Sitagliptin, an oral hypoglycemic agent for patients
with T2DM, was used as the control group due to its neutral
effect on cardiovascular outcomes in randomized clinical
trials while having similar glucose-lowering efficacy to that
of SGLT2is [16, 17]. Additionally, sitagliptin has been used
as the control group in prior studies of SGLT2is in HFrEF
patients [18, 19]. Index date was set at the date of first prescription of SGLT2is or sitagliptin.
Patients were excluded if the transthoracic echocardiogram (TTE) closest to the index date showed a left ventricular ejection fraction less than 50% or the prescription date
of the SGLT2is or sitagliptin was before 1 January 2016.
Patients diagnosed with chronic kidney disease (CKD) stage
5 or end-stage renal disease (ESRD) on dialysis before the
index date were excluded. Moreover, patients who were prescribed both SGLT2i and sitagliptin were excluded.
Baseline characteristics including age at the time of
inclusion in the study; gender; race/ethnicity; body mass
index (BMI); estimated glomerular filtration rate (eGFR);
and co-morbidities including hypertension, hyperlipidemia,
coronary artery disease, chronic kidney disease, and cerebrovascular accident were collected. eGFR was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [20]. Mean hemoglobin a1c (HbA1c)
was shown to have a predictive value for HFH in prior studies and therefore included in our study [21]. Medications
commonly used in HFrEF (angiotensin-converting enzyme
inhibitors (ACEis), angiotensin II receptor blockers (ARBs),
angiotensin receptor neprilysin inhibitor (ARNi), beta-blockers (BBs), and spironolactone) and T2DM (metformin and
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insulin) were collected as possible confounding variables.
In the SGLT2i group, patients' insurance information and
SGLT2i prescriber information were collected. The followup period was set as 300 days after the index date. Patients
were selected based on eligibility criteria with the help of the
Clinical Looking Glass (CLG, Streamline Health, Atlanta,
GA, USA), which is a user-friendly software that can help
clinical researchers navigate through electronic medical
records (EMRs) and select cohorts of eligible patients [22].
The institutional review board of Albert Einstein College
of Medicine approved the study.

2.2 Data Extraction
Two researchers (WL, AK) independently reviewed each
patient's EMR to extract and document relevant information in a pre-designed data extraction sheet. The follow-up
was available until the time of death or 300 days from the
index date. Subjects who reached clinical outcomes (hospitalization, acute kidney injury) were censored when the first
event occurred during the follow-up period. If the index date
was during hospitalization, subjects were censored when the
first hospitalization occurred after hospital discharge or the
time of death or 300 days after index date for hospitalization
outcomes.

2.3 Outcome and Statistical Analysis
The primary outcome was the first occurrence of hospitalization for acute decompensated heart failure, as first heart
failure hospitalization has been found to be predictive of
future events [23]. The secondary outcomes were all-cause
hospitalization and acute kidney injury. Acute kidney injury
as defined by KDIGO (Kidney Disease Improving Global
Outcomes)—“An absolute increase in serum creatinine at
least 0.3 mg/dL within 48 h or by a 50% increase in serum
creatinine from baseline within seven days, or a urine volume of less than 0.5 mL/kg/h for at least 6 h"—was used
[24]. Heart failure hospitalization was defined as acute
decompensated heart failure resulting in hospitalization.
Continuous variables were described as mean ± standard
deviation. Categorical variables were reported as absolute
numbers and percentages. The standardized mean difference
(SMD) is calculated to assess the difference between the two
groups [25]. Propensity score matching using nearest neighbor matching with a caliper of 0.1 standard deviation of the
logit of the propensity scores was conducted to improve the
comparability between the two groups. The baseline characteristics including, age, gender, race/ethnicity, hypertension, hyperlipidemia, coronary artery disease, chronic kidney disease, cerebrovascular accident, eGFR, mean BMI,
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mean hemoglobin A1c, and other confounding medications,
were incorporated into the propensity score matching. Age,
gender, and race/ethnicity have been found to be significant sociodemographic risk factors for heart failure hospitalization [26, 27]. Coronary artery disease, chronic kidney
disease, and cerebrovascular disease were included due to
association with the risk of heart failure hospitalization [28,
29]. Mean hemoglobin A1c was included to offset the glycemic effects related to heart failure adverse events [30].
Hypertension, hyperlipidemia, and obesity are common
co-morbidities associated with HFpEF [27]. Confounding
medications are either part of established guideline-directed
medical therapy (GMDT) for HFrEF or common medications used in type 2 diabetes mellitus. One-to-two ratio
matching was adopted to preserve sample size. An SMD
less than 0.1 is considered well matching between the two
groups. Univariate Cox regression was performed individually for each study outcome: HFH, all-cause hospitalization,
and AKI risk between the SGLT2i group and the sitagliptin
group. Cox regression results were provided as the hazard
ratio (HR) with the 95% confidence interval (CI) and twosided p-values. The time-to-outcome analysis was performed
using the Kaplan-Meier method and the log-rank test was
used. The threshold of statistical significance was p < 0.05.
All analyses were conducted using R 3.6.3 version (RStudio
software, RStudio, Inc.).

3 Results
A total of 845 patients were eligible for study enrollment;
after screening there were 149 patients in the SGLT2i group
and 696 patients in the sitagliptin group. After further exclusion and propensity score matching, the SGLT2i group contained 89 patients, and the sitagliptin group consisted of 161
patients (Fig. 1). The matched cohorts were balanced for
age, gender, race/ethnicity, clinical co-morbidities such as
HTN and HLD, eGFR, mean BMI, and mean HbA1c, and
prescriptions of other medications with SMDs less than 0.10
(Table 1).

3.1 Primary Outcome: Heart Failure Hospitalization
A total of 4.5% (4/89) patients in the SGLT2i group and
29.8% (48/161) patients in the sitagliptin group were hospitalized for acute decompensated heart failure during a mean
follow-up of 295 days. Univariate Cox regression analysis
showed that the SGLT2i group had a significantly lower
occurrence of heart failure hospitalization compared to the
sitagliptin group within the study period (HR 0.13; 95% CI
(0.05–0.36); p < 0.001) (Fig. 2).

56

W. Li et al.

845 paents were eligible for study
enrollment during screening

149 paents were included in SGLT2i
group

696 paents were included in
Sitaglipn group

101 paents were qualified for the
inclusion criteria aer review

394 paents were qualified for the
inclusion criteria aer review

17 paents with LVEF<50%

36 paents with LVEF<50%

10 paents not receiving SGLT2is due
to payment issue or not tolerang the
medicaons

212 paents with first prescripon of
Sitaglipn before study period

4 paents with first prescripon of
SGLT2is before study period

54 paents were diagnosed of ESRD
and started on hemodialysis before
index date

1 paent was diagnosed of ESRD and
started on hemodialysis before index
Date
16 paents received both SGLT2is and
Sitaglipn at the same me during
study period
1:2 propensity score matching

89 paents in SGLT2i group

161 paents in Sitaglipn group

Fig. 1  Flow chart showing patient selection and propensity score matching

3.2 Secondary Outcomes
3.2.1 All‑Cause Hospitalization
In the SGLT2i group, 39.3% (35/89) of patients were hospitalized, while 65.8% (106/161) of patients in the sitagliptin
group were hospitalized during a mean follow-up period of

295 days. Univariate Cox regression analysis showed that
the SGLT2i group had a significantly lower occurrence of
all-cause hospitalization than the sitagliptin group within
the study period (HR 0.48; 95% CI (0.33–0.70); p < 0.001)
(Fig. 2).
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Table 1  Baseline demographic and clinical co-morbidities between the sodium-glucose cotransporter-2 inhibitor (SGLT2i) group and the sitagliptin group
Unmatched

Number of patients
Age [mean (SD)]
Male gender (%)
Race/ethnicity (%)
Asian
African American
White
Hispanic
BMI (kg/m2)
eGFR (mL/min/1.73 m
 2)
Hypertension (%)
Hyperlipidemia (%)
Coronary artery disease (%)
Chronic kidney disease (%)
Cerebrovascular accident (%)
Mean hemoglobin A1c
ACEi/ARB/ARNi (%)
Beta blocker (%)
Spironolactone (%)
Metformin (%)
Insulin (%)
Follow-up time (d)

Matched

SGLT2i group

Sitagliptin group

101
66 (12)
36 (35.6)

394
72 (13)
143 (36.3)

13 (12.9)
35 (34.7)
16 (15.8)
37 (36.6)
33.9 (8.3)
65.9 (23.0)
101 (100.0)
77 (76.2)
50 (49.5)
43 (42.6)
11 (10.9)
8.6 (1.4)
66 (65.3)
57 (56.4)
23 (22.8)
42 (41.6)
65 (64.4)
296.0 (23.9)

18 (4.6)
138 (35.0)
74 (18.8)
164 (41.6)
32.0 (9.2)
55.7 (26.2)
380 (96.4)
306 (77.7)
202 (51.3)
250 (63.5)
58 (14.7)
8.3 (1.9)
206 (52.3)
228 (57.9)
34 (8.6)
130 (33.0)
170 (43.1)
284.6 (55.8)

SMD
0.440
0.014
0.304

0.218
0.414
0.271
0.034
0.035
0.428
0.115
0.187
0.268
0.029
0.396
0.178
0.435
0.265

SGLT2i group

Sitagliptin group

89
68 (12.2)
31 (34.8)

161
69 (13.3)
55 (34.2)

7 (7.9)
32 (36.0)
16 (18.0)
34 (38.2)
33.8 (8.6)
64.8 (23.4)
89 (100.0)
69 (77.5)
45 (50.6)
42 (47.2)
10 (11.2)
8.6 (1.4)
56 (62.9)
51 (57.3)
17 (19.1)
37 (41.6)
56 (62.9)
295.4 (25.4)

11 (6.8)
57 (35.4)
30 (18.6)
63 (39.1)
33.3 (9.4)
62.6 (26.4)
161 (100.0)
129 (80.1)
79 (49.1)
80 (49.7)
18 (11.2)
8.8 (2.1)
101 (62.7)
98 (60.9)
25 (15.5)
64 (39.8)
100 (62.1)
295.8 (28.4)

SMD
0.093
0.014
0.045

0.064
0.087
<0.001
0.064
0.030
0.050
0.002
0.068
0.004
0.073
0.095
0.037
0.017
0.016

BMI body mass index, eGFR estimated glomerular filtration rate, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor
blocker, ARNi angiotensin receptor-neprilysin inhibitor

3.2.2 Acute Kidney Injury
Among patients taking SGLT2is, 12.4% (11/89) developed
acute kidney injury (AKI) during a mean follow-up of 295
days, and 29.2% (47/161) of the patients taking sitagliptin
developed AKI. Univariate Cox regression demonstrated
that within study period, acute kidney injury occurred significantly less in the SGLT2i group compared with the sitagliptin group (HR 0.39; 95% CI (0.20–0.74); p = 0.004)
(Fig. 2).

3.3 Prescriber and Insurance Information
of Sodium‑Glucose Cotransporter 2 Inhibitors
(SGLT2is)
Empaglif lozin was the most commonly prescribed
SGLT2i used in our cohort [58.4% (52/89)]. Other
SGLT2is were dapagliflozin 19.1% (17/89) and canagliflozin 22.5% (20/89). All patients in the SGLT2i group
had insurance coverage, with 87.6% of patients having

government-issued insurance under the supervision of
the Center of Medicare and Medicaid (CMS). Most of the
patients (46.1%) in the SGLT2i group had Medicaid, a
public health insurance for people with low income. The
majority of the SGLT2is were prescribed by general internal medicine physicians (50.6 %), followed by endocrinologists (27.0%) and cardiologists (12.4%) (Fig. 3).

4 Discussion
The main findings of our retrospective cohort study of
HFpEF patients with T2DM are as follows: (1) Patients
started on SGLT2is are 87% less likely to be hospitalized
for heart failure exacerbation compared to those started on
sitagliptin during the first 300 days after initiation of these
medications. (2) SGLT2i use is associated with a lower
risk of developing AKI among patients with T2DM and
HFpEF. (3) General internal medicine physicians are prescribing SGLT2is in T2DM and HFpEF more often than
cardiologists.
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Fig. 2  Comparison of cumulative incidence of primary and secondary outcomes between SGLT2i group and sitagliptin group

HFHs are associated with decreased quality of life, higher
mortality, and increased economic burden on the healthcare system [31]. The association between SGLT2i use and
reduced hospitalization risk in our study has a potential
clinical and economic impact. HFpEF-associated heart failure hospitalizations continue to increase in the USA [32].
Unlike HFrEF, there is a lack of GDMT to reduce the hospitalization rate for patients with HFpEF. Since large-sized
randomized clinical trials have demonstrated the positive
effects of SGLT2is on the reduction of hospitalization in
patients with HFrEF, SGLT2is might help HFpEF patients
as well [6, 19]. SGLT2is inhibit the reabsorption of sodium
and glucose from the proximal convoluted tubule, resulting in reduced fluid overload [33]. It is also proposed that
SGLT2is can reduce left ventricular mass and improve diastolic function by inhibiting cardiac fibrosis [34]. Fluid overload is associated with increased heart failure hospitalization
and cardiovascular mortality in HFpEF patients. SGLT2is
could reduce fluid overload by causing diuresis in combination with loop diuretics, especially in patients with diabetes

[35]. Studies have suggested that SGLT2is can have an even
stronger diuresis effect than loop diuretics since two-thirds
of filtered sodium were reabsorbed through the proximal
convoluted tubules [36, 37]. Furthermore, the theoretical
benefits of SGLT2is may be the reason behind the clinical
outcomes seen in our study.
AKI is common in heart failure patients, and an increased
number of AKI episodes increases hospitalization risk [38].
Our study revealed that in patients with HFpEF and T2DM,
the use of SGLT2is was associated with a lower AKI risk. A
meta-analysis by Neuen et al. reported that SGLT2i use was
associated with a reduced incidence of AKI in patients with
T2DM [39]. Our study has demonstrated that in patients
suffering from both HFpEF and T2DM, SGLT2is can still
achieve such benefits. Furthermore, multicenter randomized
controlled trials suggested SGLT2i use is associated with a
slower decline in kidney function and progression to endstage kidney disease [40]. The renal protective effect of
SGLT2is is likely multifactorial. SGLT2is are theorized to
decrease intraglomerular pressure, suppress inflammation,
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Fig. 3  Insurance and prescriber information for SGLT2is

reduce oxidative stress, and improve the energy consumption
of the kidney [41]. These possible mechanisms may likely
explain our findings.
With this new group of medications that overlap disease
categories, the question of who should or who is best to prescribe these is relevant. Current studies indicate internists or
endocrinologists but not cardiologists are the most common
prescribers of SGLT2is. The prescription of SGLT2is among
cardiologists has been low, and only 4.5% of total annual
prescriptions of SGLT2is in a retrospective study conducted
at a multicenter health system came from cardiologists [42].
Our study found a similar prescription pattern of SGLT2is in
patients with both T2DM and HFpEF (Fig. 3). This might be
related to unfamiliarity with the expanded applications of the
SGLT2is and concerns of possible side effects of SGLT2is
such as euglycemic diabetic ketoacidosis and urinary tract
infections. An increase in awareness of the benefits of
SGLT2is in cardiac patients could improve prescription patterns of SGLT2is among cardiologists.
Lastly, most of the patients in our cohort receiving
SGLT2is were either Medicare or Medicaid beneficiaries

(Fig. 3). As a novel class of medications, patients who are
Medicare or Medicaid beneficiaries could face high out-ofpocket charges despite coverage as well as other obstacles to
obtaining these medications [27, 43]. Our study shows that
the part of Medicare or Medicaid beneficiaries who received
SGLT2is successfully had their associated clinical benefits.
Our findings should encourage future prescriptions of this
class of drugs to all patients and possible healthcare coverage reform.
Our study added to the current literature that SGLT2is
could not only decrease hospitalization for heart failure
patients with reduced ejection fraction [6, 7], but also
for those with preserved ejection fraction, which is an
increasingly prevalent clinical syndrome with a growing
number of hospitalizations annually [44].
The main strengths of our study include its strict
methodology with propensity score matching of possible confounding factors, careful selection of patient
cohort, and robust analysis. Our patient population is
truly diverse and mainly consisted of racial and ethnic
minorities, with Black and Hispanic participants forming
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a majority—groups who can be under-represented in randomized multicenter studies. In addition, studies have
shown that Black patients have a significantly higher rate
of HFH [45]. Representation of this population in our
study is therefore relevant and complements the results
of randomized controlled trials.
On the other hand, we would like to acknowledge a
few limitations of our study, mainly associated with its
observational nature. Since SGLT2is are a novel class of
medications, patients in the SGLT2i groups can be early
adopters with other hidden unadjusted confounding variables. Our study is limited by its relatively small sample
size, lacking sufficient power to detect the difference in
mortality outcome between the SGLT2i group and the
sitagliptin group. We also note that a few patients in the
SGLT2i group were on GLP1 receptor agonists as well.
While there are many agents in the SGLT2i class of
medications, we feel that there is a class effect whereby
the mechanisms of interest are sufficiently similar to consider them as one group [6, 7, 9, 10].
While not a randomized clinical trial, we sought a
control group that would allow for statistical comparison to further support our findings. Sitagliptin is also
a relatively newer drug with a different mechanism to
SGLT2is. Unlike the other dipeptidyl peptidase-4 (DPP4) inhibitors such as saxagliptin and alogliptin, sitagliptin
has not been found to be associated with increased risk
of HFH [16, 46].
Our study is hypothesis-generating and provides information that can help with the development of future randomized prospective studies with a large-size sample of
patients. Randomized clinical trials such as the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt
Failure With Preserved Ejection Fraction (EMPERORPreserved) study of empagliflozin and Dapagliflozin
Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) study
of dapagliflozin for HFpEF are in progress with the aim
of improving our clinical practice in HFpEF patients [47,
48].

5 Conclusion
The use of SGLT2is is associated with significantly
reduced hospitalization and fewer events of AKI in a
diverse population of patients with heart failure with preserved ejection fraction and T2DM. The prescription of
SGLT2is for heart failure with preserved ejection fraction
from cardiologists remains low.
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